Opendata, web and dolomites

ImmunoGrow

Making life-saving cancer therapies more widely available by simplifying production processes, reducing costs and enhancing patient safety through its patent-protected biomimicking mesh material.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ImmunoGrow project word cloud

Explore the words cloud of the ImmunoGrow project. It provides you a very rough idea of what is the project "ImmunoGrow" about.

mesh    operator    gmt    core    activation    gold    produces    significantly    cell    performance    cancers    patients    struggling    customers    2021    reduce    prices    standard    changing    15    closed    structure    labour    full    initial    reducing    patent    capture    q3    fund    yield    seeking    shown    anticipated    limited    600mn    seed    lifesaving    treatment    poor    8x    life    body    infrastructure    publically    consumables    475    cheaper    dynabeads    harness    genetically    technologies    expects    remission    independent    conduct    feasibility    round    skilled    lab    prohibitive    costly    citizens    simplifying    therapies    sickest    83    priced    healthcare    solutions    cancer    release    addressable    500    2030    variability    immune    safer    ltd    manufacture    market    save    requirement    limitations    ing    treatments    business    cleanroom    achieves    protected    plan    aggressive    unless    helps    patient    trials    cells    mimics    expensive    rates    grey    2019    engineered    input    individualised    natural    tests    car    untreatable    manufacturers    encounter    automated    immunogrow   

Project "ImmunoGrow" data sheet

The following table provides information about the project.

Coordinator
Grey Matter Technologies Limited 

Organization address
address: MERTON BREE ENNISCORTHY
city: WEXFORD
postcode: Y21 Y5V0
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.immunogrow.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Grey Matter Technologies Limited IE (WEXFORD) coordinator 50˙000.00

Map

 Project objective

Lifesaving cell-based CAR-T therapies have achieved remission rates of up to 83% for patients with the most aggressive and untreatable cancers. These therapies harness a patient’s own genetically engineered immune cells to target cancer cells. However, manufacturers are struggling to produce these individualised treatments at scale resulting in prohibitive prices as high as $475,000 per treatment. Unless solutions that address these limitations are provided, publically-funded EU healthcare systems & citizens will be priced out of these life-changing therapies.

The challenges they face include poor cell growth performance due to patient sample variability, limitations associated with equipment adopted from the research lab that require costly skilled labour, costly consumables and expensive cleanroom infrastructure.

Compared to the gold standard, Dynabeads, initial testing has shown that the ImmunoGrow technology produces an 8x higher cell yield which helps to save the sickest patients who have limited cells and significantly reduce the cost to manufacture these therapies by simplifying the process, reducing the requirement for skilled operator input and making this step both ‘closed’ and automated. ImmunoGrow achieves this through its patent-protected mesh structure that mimics the natural growth conditions cells encounter in the body.

Grey Matter Technologies (‘GMT’) Ltd. is seeking support to help fund trials with two identified customers as well to help it to conduct an independent set of tests on the product’s performance. Both these trials, as well as an associated business plan or feasibility study, will be core to the raising of a seed round of €500,000 in 2019 to further develop the technology with the release of a full-scale product anticipated for Q3 2021. GMT expects to capture 15% of the $600mn addressable T-Cell Activation market in 2030. In doing so, it will make these life changing treatments cheaper, safer and more widely available.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOGROW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOGROW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

SiC-MOSFET (2019)

Gas Sensors for future Ultra Low NOx Emission Legislation – Euro 7

Read More  

COUNTMITMENT (2019)

NATURAL CAPITAL ACCOUNTANCY TO IMPROVE REPORTING AND ENVIRONMENTAL PERFORMANCE

Read More